Evidence map›Paper›PMID 40007032›Full record

ArticleViruses2025

Heterologous Immunization with Improved HIV-1 Subtype C Vaccines Elicit Autologous Tier 2 Neutralizing Antibodies with Rapid Viral Replication Control After SHIV Challenge.

Gerald K Chege, Rosamund E Chapman, Alana T Keyser, Craig H Adams, Kealan Benn, Michiel T van Diepen, Nicola Douglass, Bronwen Lambson, Tandile Hermanus, Penny L Moore and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gerald K ChegePrimate Unit and Delft Animal Centre, Centre and Platform Office, South African Medical Research Council, Parrow Valley, Cape Town 7505, South Africa.ORCID 0000-0003-3986-9638
Rosamund E ChapmanDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0001-9162-2099
Alana T KeyserDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Craig H AdamsDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Kealan BennDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Michiel T van DiepenDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0001-8156-4294
Nicola DouglassDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0002-8929-6279
Bronwen LambsonSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2000, South Africa.
Tandile HermanusSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2000, South Africa.
Penny L MooreSA MRC Antibody Immunity Research Unit, School of Pathology, University of the Witwatersrand, Johannesburg 2000, South Africa.ORCID 0000-0001-8719-4028
Anna-Lise WilliamsonDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.ORCID 0000-0002-5467-1200

Funding

South African Medical Research Council with funds received from the South African Department of Science and Innovation. PLM is supported by the South African Research Chairs Initiative of the De-partment of Science and Innovation and the National Research 98341
6 · The paper itself

Abstract

We previously reported on HIV vaccines that elicited autologous Tier 2 neutralizing antibodies (nAbs) in rabbits. In the current study, we sought to establish a proof of concept that HIV vaccines using identical designs elicit Tier 2 nAbs in arhesus macaque (RM) model. DNA and MVA vaccines expressing SIV Gag and HIV-1 Env antigens were constructed, and in vitro expression was confirmed. A soluble envelope protein (gp140 Env) was expressed from a stable HEK293 cell line and purified using lectin affinity and size exclusion chromatography. The expression and secretion of SIV Gag and HIV-1 Env by the DNA and MVA vaccines was verified in vitro. Five RMs were inoculated with two DNA, followed by two MVA, and finally with two gp140 Env vaccines at weeks 0, 4, 8, 12, 20 and 28. Vaccine-induced T cell immunity was measured by IFN-γ ELISpot while nAbs were evaluated against MW965 (Tier 1A), 6644 (Tier 1B), autologous ZM109.5A and a closely-related ZM109.B4 (Tier 2) pseudovirions. Vaccinated RMs were challenged intrarectally with simian-human immunodeficiency virus (SHIV), four weeks after the final vaccination, as was an unvaccinated control group (

Indexed as

AIDS VaccinesAntibodies, NeutralizingHIV-1HIV AntibodiesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVirus ReplicationAnimalsenv Gene Products, Human Immunodeficiency VirusHEK293 CellsHIV InfectionsHumansImmunization, SecondaryMacacaSAIDS VaccinesVaccines, DNAAIDS VaccinesAntibodies, Neutralizingenv Gene Products, Human Immunodeficiency Virusgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesSAIDS VaccinesVaccines, DNAChinese rhesus macaquesDNA vaccinegp140 EnvimmunogenicityMVA vaccineneutralizationSHIV

Identifiers

PMID40007032
PMCPMC11861162

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.